Prognostic value of PCSK9 levels in patients with acute coronary syndromes
Prognostic value of PCSK9 levels in patients with acute coronary syndromes
复制标题
DOI：
10.1093/eurheartj/ehv637
复制
发表时间：
2016-02-07
影响因子：
39.3
通讯作者：
Mach, Francois
中科院分区：
文献类型：
--
作者：
Gencer, Baris;Montecucco, Fabrizio;Mach, Francois
前蛋白转化酶枯草杆菌蛋白酶kexin 9（PCSK 9）是治疗高胆固醇血症的新靶点，但PCSK 9水平指导治疗的临床效用尚不清楚。我们的目的是前瞻性地评估血浆PCSK9水平在急性冠状动脉综合征（ACS）患者的预后价值。方法和结果血浆PCSK9水平测定在2030 ACS患者进行冠状动脉造影在瑞士前瞻性队列。在1年时，评估了PCSK 9三分位数与全因死亡之间的相关性，调整了急性冠脉事件全球登记（GRACE）变量，以及LDL胆固醇目标的实现，
Aims Proprotein convertase subtilisin kexin 9 (PCSK9) is an emerging target for the treatment of hypercholesterolaemia, but the clinical utility of PCSK9 levels to guide treatment is unknown. We aimed to prospectively assess the prognostic value of plasma PCSK9 levels in patients with acute coronary syndromes (ACS).Methods and results Plasma PCSK9 levels were measured in 2030 ACS patients undergoing coronary angiography in a Swiss prospective cohort. At 1 year, the association between PCSK9 tertiles and all-cause death was assessed adjusting for the Global Registry of Acute Coronary Events (GRACE) variables, as well as the achievement of LDL cholesterol targets of